Dataset Information

Symmetric dimethylarginine concentrations in healthy neonatal foals and mares.

ABSTRACT:

Background

Symmetric dimethylarginine (SDMA) is a renal biomarker correlated with glomerular filtration rate (GFR).

Objectives

Describe changes in SDMA in clinically healthy foals and their mares during the first month postfoaling.

Animals

Convenience sampling of healthy periparturient Thoroughbred mares and their full-term foals from a population of client-owned horses.

Methods

Serum and EDTA whole blood samples were collected from mares in their last month of pregnancy and then from mares and foals at approximately <12 hours, 48 hours, 7 days, and 30 days postbirth. Samples were processed at a commercial reference laboratory for CBC and serum biochemistry, including SDMA concentrations.

Results

A total of 125 foals and 104 mares were included. Upper limits for SDMA concentrations in foals were above the adult horse reference interval for the first 20 or more days of life. Median SDMA concentrations decreased from 70 μg/dL (range, 7-100 μg/dL) to 18 μg/dL (range, 6-27 μg/dL) during the first 3 to 4 weeks of life. At birth, the SDMA concentration reference range was established as 0 to 100 μg/dL (upper limit of the assay); 0 to 85 μg/dL for 1 to 4 days old, 0 to 36 μg/dL for 5 to 10 days old, and 0 to 24 μg/dL for 20 to 30 days old. The upper reference limits for SDMA concentrations in mares did not differ from the general reference interval for adult horses. No correlation was identified between mare and foal SDMA concentrations (ρ = .06, P = .58).

Conclusions and clinical importance

Foal SDMA concentrations remained higher than the upper limit of the adult reference range and foals require a different reference range dependent on age.

SUBMITTER: Bozorgmanesh R

PROVIDER: S-EPMC8692187 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Symmetric dimethylarginine concentrations in healthy neonatal foals and mares.

Bozorgmanesh Rana R Thornton Jessica J Snyder Jackie J Fletcher Caitlin C Mack Rebekah R Coyne Michael M Murphy Rachel R Hegarty Evan E Slovis Nathan N

Journal of veterinary internal medicine 20211105 6

<h4>Background</h4>Symmetric dimethylarginine (SDMA) is a renal biomarker correlated with glomerular filtration rate (GFR).<h4>Objectives</h4>Describe changes in SDMA in clinically healthy foals and their mares during the first month postfoaling.<h4>Animals</h4>Convenience sampling of healthy periparturient Thoroughbred mares and their full-term foals from a population of client-owned horses.<h4>Methods</h4>Serum and EDTA whole blood samples were collected from mares in their last month of pregn ...[more]

PMID: 34738665

Similar Datasets

Project description:IntroductionRenin-angiotensin-aldosterone system inhibition (RAASi) reduces intraglomerular pressure and is a standard therapy for dogs with proteinuric chronic kidney disease (CKD). RAASi can acutely decrease glomerular filtration rate (GFR); however, its effects on the marker of GFR serum symmetric dimethylarginine (SDMA) concentration in dogs have not been specifically evaluated. The objective of this study was to evaluate changes, relative to pretreatment values, in serum SDMA concentrations in dogs with proteinuric CKD receiving RAASi therapy.MethodsThis retrospective study used banked samples from 29 dogs with proteinuric CKD treated with enalapril (0.5 mg/kg PO q12h; n = 16) or telmisartan (1 mg/kg PO q24h; n = 13) alone (n = 22) or in combination with amlodipine if severely hypertensive (n = 7). Serum SDMA, creatinine, and urea nitrogen (SUN) concentrations were measured before and 7 and 30 days after starting RAASi. Percentage and absolute changes in these biomarkers were calculated for each dog and time point. A linear mixed model was used to test whether changes significantly differed from zero (α < 0.05).ResultsOverall, mean ± SEM Day 7 and 30 percentage change in SDMA were - 4.8 ± 3.6% and - 3.2 ± 3.4%, respectively; in creatinine were 7.4 ± 3.3% and 3.0 ± 3.1%, respectively; and in SUN were 22.1 ± 6.8% and 16.7 ± 6.2%, respectively. Mean changes varied according to whether all dogs, those on RAASi alone, or those co-treated with amlodipine were evaluated. In dogs receiving RAASi alone, at day 7, there were significant mean percentual increases in creatinine (9%; p = 0.023) and SUN (23%; p = 0.005), but SDMA was unchanged. In dogs co-treated with amlodipine, a significant absolute decrease in mean SDMA (-2.29 μg/dL; p = 0.026) occurred at days 7 and 30, while mean creatinine was unchanged and mean SUN increased.DiscussionProteinuric dogs receiving RAASi had low-magnitude changes in serum SDMA and creatinine, and moderate-magnitude changes in SUN concentrations. The direction of change in SDMA did not consistently match that of creatinine and SUN.

Project description:BackgroundIt is unknown if tumors or concomitant renal disease influence neutrophil gelatinase-associated lipocalin (NGAL) and symmetric dimethylarginine (SDMA) concentrations in tumor-bearing dogs.ObjectivesDetermine the effect of tumor presence, tumor type, and metastasis on concentrations of serum NGAL (sNGAL), SDMA, urinary NGAL (uNGAL), and uNGAL-to-creatinine ratio (uNGAL/Cr) in dogs with carcinoma or sarcoma without clinically relevant renal disease.AnimalsTwenty-one dogs with carcinoma, 18 with sarcoma, and 20 healthy age-controlled dogs.MethodsConcentrations of sNGAL, SDMA, and uNGAL, and uNGAL/Cr ratio were measured from banked samples collected during a previous prospective study. Patient clinicopathological and histopathology records were reviewed, and those with renal azotemia or moderate to severe histopathological renal abnormalities were classified as having clinically relevant renal disease. Biomarker concentrations were compared between tumor-bearing dogs without clinically relevant renal disease and healthy age-controlled dogs. Additionally, comparisons were made between dogs with carcinoma and sarcoma, as well as between dogs with and without metastasis. Correlations between uNGAL and sNGAL concentrations, along with acute phase protein (APP) concentrations, were also analyzed.ResultsTumor-bearing dogs without clinically relevant renal disease had increased uNGAL/Cr (p < 0.001), but not sNGAL, compared with healthy controls. Although median SDMA concentrations did not significantly differ between groups, increased concentrations were found in 32% of dogs with carcinoma and 20% of dogs with sarcoma. No differences were found between dogs with carcinoma and those with sarcoma, or between dogs with metastasis and those without. Urinary and serum NGAL concentrations were moderately correlated, while weak to no correlations were observed with APPs.ConclusionCarcinomas and sarcomas, but not metastasis, influence uNGAL/Cr and SDMA concentrations in dogs.

Dataset Information

Symmetric dimethylarginine concentrations in healthy neonatal foals and mares.

Background

Objectives

Animals

Methods

Results

Conclusions and clinical importance

Publications

Symmetric dimethylarginine concentrations in healthy neonatal foals and mares.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets